Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NDV-3 + alum
- Development stage
- Unknown
- Lead developer
- NovaDigm Therapeutics
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Intradermal
01
Overview
NDV-3 + alum is an investigational recombinant protein subunit vaccine developed by NovaDigm Therapeutics. It consists of the N-terminal portion of the *Candida albicans* agglutinin-like sequence 3 protein (Als3p), expressed in *Saccharomyces cerevisiae* and formulated with an aluminum hydroxide (alum) adjuvant in phosphate-buffered saline. The vaccine targets the Als3p virulence protein, which is essential for the adhesion and invasion of host tissues by *Candida* species. Due to structural homology between Als3p and certain surface proteins on *Staphylococcus aureus*, the vaccine also induces cross-reactive immune responses against staphylococcal infections. NDV-3 has been evaluated in Phase 1 clinical trials for the prevention and treatment of various forms of candidiasis and *S. aureus* skin and bloodstream infections. A successor formulation, NDV-3A, was subsequently developed without a His-tag.
- Other names
- NDV-3 vaccineNDV3 vaccineNDV 3 vaccineAls3p vaccineAls-3p vaccineAls 3p vaccine
02
Targets
Als3 (Agglutinin-like sequence protein 3)
Beyond the preview
Go deeper on NDV-3 + alum.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NDV-3 + alum.